408
Participants
Start Date
January 20, 2022
Primary Completion Date
April 30, 2024
Study Completion Date
August 30, 2024
KN046
KN046+Nab-Paclitaxel+Gemcitabine In combine therapy stage, KN046 is 5 milligram per kilogram, every 2 weeks. In maintain stage, KN046 is 5 milligram per kilogram, every 2 weeks.
placebo
placebo+Nab-Paclitaxel+Gemcitabine In combine therapy stage, placebo is 5 milligram per kilogram, every 2 weeks. In maintain stage, placebo is 5 milligram per kilogram, every 2 weeks.
Shanghai Changhai Hospital, Shanghai
The Second Hospital Of Anhui medical University, Hefei
Beijing Cancer Hospital, Beijing
Beijing Friendship Hospital, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Chinese PLA General Hospital, Beijing
Peking Union Medical College, Beijing
Peking University Third Hospital, Beijing
Chongqing Cancer Hospital, Chongqing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
The Southwest Hospital of AMU, Chongqing
The Third Affiliated Hospital of Army Medical University, Chongqing
Fujian Cancer Hospital, Fuzhou
Fujian Medical University Union Hospital, Fuzhou
The First Affiliated Hospital of Fujian Medical University, Fuzhou
The First Affiliated Hospital of Xiamen University, Xiamen
The First Hospital of Lanzhou University, Lanzhou
Guangdong Provincial People's Hospital, Guangzhou
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
The First Affiliated Hospital,Sun Yat-sen University, Guangzhou
Affiliated Cancer Hospital of Guangxi Medical University, Nanning
The Affiliated Hospital of Guizhou Medical University, Guiyang
The Fourth Hospital of Hebei Medical University, Shijiazhuang
Harbin Medical University Cancer Hospital, Harbin
Henan Cancer Hospital, Zhengzhou
Henan Provincial People's Hospital, Zhengzhou
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Hubei Cancer Hospital, Wuhan
Renmin Hospital of Wuhan University, Wuhan
Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan
Zhongnan Hospital of Wuhan University, Wuhan
Hunan Cancer Hospital, Changsha
Hunan Provincial People's Hospital, Changsha
The Second Xiangya Hospital of Central South University, Changsha
Xiangya Hospital Central South University, Changsha
The First People's Hospital of Changzhou, Changzhou
Jiangsu Province Hospital, Nanjing
Nantong Tumor Hospital, Nantong
The Affiliated Hospital Of XuZhou Medical University, Xuzhou
First Affiliated Hospital of Nanchang University, Nanchang
The Second Affiliated Hospital of Nanchang University, Nanchang
China-Japan Union Hospital of Jilin University, Changchun
The First Hospital of Jilin University, Changchun
Liaoning Cancer Hospital, Shenyang
The First Affiliated Hospital of China Medical University, Shenyang
Shandong Cancer Hospital, Jinan
Shandong Provincial Hospital, Jinan
Affiliated Hospital of Jining Medical University, Jining
LINYI Cancer Hospital, Linyi
Linyi City People Hospital, Linyi
The Affiliated Hospital of Qingdao University, Qingdao
Weifang People'S Hospital, Weifang
Yueyang Hospital of Integrated Traditional Chinese and Western Medicine , Shanghai University of Traditional Chinese Medicine, Shanghai
Zhongshan Hospital Fudan University, Shanghai
Shanxi Cancer hospital, Taiyuan
Shanxi Provincial People's Hospital, Taiyuan
the First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Sichuan Cancer Hospital, Chengdu
Sichuan Provincial People's Hospital, Chengdu
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou
The Second Affiliated Hosipital Zhejiang University School of Medicine, Hangzhou
Zhejiang Cancer Hospital, Hangzhou
Zhejiang Provincial People's hospital, Hangzhou
Jiaxing Second Hospital, Jiaxing
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
INDUSTRY